NEWRON PHARMACEUT. EO-20
Newron Pharmaceuticals S.p.A., a biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson's in the European Union, the United Kingdom, the United States, Latin America, Switzerland, and Japan. The company's… Read more
NEWRON PHARMACEUT. EO-20 (NP5) - Net Assets
Latest net assets as of June 2025: €1.58 Million EUR
Based on the latest financial reports, NEWRON PHARMACEUT. EO-20 (NP5) has net assets worth €1.58 Million EUR as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€61.39 Million) and total liabilities (€59.81 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €1.58 Million |
| % of Total Assets | 2.58% |
| Annual Growth Rate | -12.13% |
| 5-Year Change | -91.55% |
| 10-Year Change | -96.07% |
| Growth Volatility | 174.4 |
NEWRON PHARMACEUT. EO-20 - Net Assets Trend (2005–2024)
This chart illustrates how NEWRON PHARMACEUT. EO-20's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for NEWRON PHARMACEUT. EO-20 (2005–2024)
The table below shows the annual net assets of NEWRON PHARMACEUT. EO-20 from 2005 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €1.46 Million | +104.87% |
| 2023-12-31 | €-29.91 Million | -113.17% |
| 2022-12-31 | €-14.03 Million | -551.56% |
| 2021-12-31 | €3.11 Million | -81.98% |
| 2020-12-31 | €17.25 Million | -53.13% |
| 2019-12-31 | €36.80 Million | -32.89% |
| 2018-12-31 | €54.84 Million | -19.03% |
| 2017-12-31 | €67.72 Million | +36.13% |
| 2016-12-31 | €49.75 Million | +34.05% |
| 2015-12-31 | €37.11 Million | +26.83% |
| 2014-12-31 | €29.26 Million | +38.74% |
| 2013-12-31 | €21.09 Million | -23.61% |
| 2012-12-31 | €27.61 Million | +319.26% |
| 2011-12-31 | €6.58 Million | -45.98% |
| 2010-12-31 | €12.19 Million | -58.37% |
| 2009-12-31 | €29.28 Million | -36.08% |
| 2008-12-31 | €45.81 Million | -20.19% |
| 2007-12-31 | €57.40 Million | -15.41% |
| 2006-12-31 | €67.86 Million | +298.70% |
| 2005-12-31 | €17.02 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to NEWRON PHARMACEUT. EO-20's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 2614095100.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €10.66 Million | 731.48% |
| Common Stock | €3.98 Million | 273.29% |
| Total Equity | €1.46 Million | 100.00% |
NEWRON PHARMACEUT. EO-20 Competitors by Market Cap
The table below lists competitors of NEWRON PHARMACEUT. EO-20 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
FIREWEED METALS CORP.
F:M0G
|
$331.62 Million |
|
Storytel AB (publ)
PINK:STRYF
|
$331.65 Million |
|
Synopex Inc
KQ:025320
|
$331.70 Million |
|
Jiangsu Bide Science and Technology Co. Ltd.
SHG:605298
|
$331.94 Million |
|
EPIC Suisse AG
SW:EPIC
|
$331.03 Million |
|
Danhua Chemical Technology Co Ltd A
SHG:600844
|
$330.83 Million |
|
Hollyland China Electronics Technology Corp Ltd
SHE:002729
|
$330.83 Million |
|
Chongqing Water Group Co Ltd
SHG:601158
|
$330.74 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in NEWRON PHARMACEUT. EO-20's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -29,908,000 to 1,458,000, a change of 31,366,000.
- Net income of 15,843,000 contributed positively to equity growth.
- New share issuances of 15,414,000 increased equity.
- Other comprehensive income increased equity by 12,081,000.
- Other factors decreased equity by 11,972,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €15.84 Million | +1086.63% |
| Share Issuances | €15.41 Million | +1057.2% |
| Other Comprehensive Income | €12.08 Million | +828.6% |
| Other Changes | €-11.97 Million | -821.12% |
| Total Change | €- | % |
Book Value vs Market Value Analysis
This analysis compares NEWRON PHARMACEUT. EO-20's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 229.94x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 2.99x to 229.94x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2005-12-31 | €6.03 | €18.06 | x |
| 2006-12-31 | €17.90 | €18.06 | x |
| 2007-12-31 | €9.84 | €18.06 | x |
| 2008-12-31 | €7.68 | €18.06 | x |
| 2009-12-31 | €4.81 | €18.06 | x |
| 2010-12-31 | €1.84 | €18.06 | x |
| 2011-12-31 | €0.91 | €18.06 | x |
| 2012-12-31 | €3.38 | €18.06 | x |
| 2013-12-31 | €1.83 | €18.06 | x |
| 2014-12-31 | €2.31 | €18.06 | x |
| 2015-12-31 | €2.70 | €18.06 | x |
| 2016-12-31 | €3.39 | €18.06 | x |
| 2017-12-31 | €4.15 | €18.06 | x |
| 2018-12-31 | €3.07 | €18.06 | x |
| 2019-12-31 | €2.06 | €18.06 | x |
| 2020-12-31 | €0.97 | €18.06 | x |
| 2021-12-31 | €0.17 | €18.06 | x |
| 2022-12-31 | €-0.79 | €18.06 | x |
| 2023-12-31 | €-1.68 | €18.06 | x |
| 2024-12-31 | €0.08 | €18.06 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently NEWRON PHARMACEUT. EO-20 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 1086.63%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 30.83%
- • Asset Turnover: 0.80x
- • Equity Multiplier: 43.83x
- Recent ROE (1086.63%) is above the historical average (-14.36%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2005 | -87.66% | 0.00% | 0.00x | 1.38x | €-16.62 Million |
| 2006 | -24.17% | -1377.08% | 0.01x | 1.27x | €-23.19 Million |
| 2007 | -19.32% | -275.57% | 0.06x | 1.23x | €-16.83 Million |
| 2008 | -35.72% | -416.07% | 0.06x | 1.32x | €-20.95 Million |
| 2009 | -80.19% | -923.72% | 0.06x | 1.42x | €-26.41 Million |
| 2010 | -168.53% | -2549.01% | 0.04x | 1.57x | €-21.76 Million |
| 2011 | -97.87% | -2301.79% | 0.02x | 2.06x | €-7.10 Million |
| 2012 | -8.60% | -26.61% | 0.20x | 1.62x | €-5.14 Million |
| 2013 | -33.66% | -200.57% | 0.11x | 1.50x | €-9.21 Million |
| 2014 | -34.50% | -648.36% | 0.04x | 1.27x | €-13.02 Million |
| 2015 | -61.48% | -958.66% | 0.05x | 1.20x | €-26.53 Million |
| 2016 | -30.63% | -226.54% | 0.12x | 1.14x | €-20.21 Million |
| 2017 | -7.80% | -39.34% | 0.18x | 1.08x | €-12.05 Million |
| 2018 | -27.42% | -373.54% | 0.07x | 1.09x | €-20.52 Million |
| 2019 | -54.91% | -287.11% | 0.12x | 1.64x | €-23.89 Million |
| 2020 | -121.76% | -399.35% | 0.10x | 2.97x | €-22.72 Million |
| 2021 | -479.59% | -258.61% | 0.11x | 16.25x | €-15.21 Million |
| 2022 | 0.00% | -287.05% | 0.16x | 0.00x | €-16.09 Million |
| 2023 | 0.00% | -179.13% | 0.35x | 0.00x | €-13.23 Million |
| 2024 | 1086.63% | 30.83% | 0.80x | 43.83x | €15.70 Million |
Industry Comparison
This section compares NEWRON PHARMACEUT. EO-20's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| NEWRON PHARMACEUT. EO-20 (NP5) | €1.58 Million | -87.66% | 37.81x | $331.04 Million |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |